ReviewCurrent diabetes reports2017
Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome.
Review in Current diabetes reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Gut microbiome and blood glucose control in type 1 diabetes: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Associations Between Serum Fatty Acids and Immunological Markers in Children Developing Islet Autoimmunity-The TRIGR Nested Case-Control Study.Frontiers in immunology · 2022Trial
- Adjuvant Probiotics ofFrontiers in endocrinology · 2022Trial
- Lack of effect ofBMJ open diabetes research & care · 2021Trial
- Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case-control ancillary study.Diabetologia · 2020Trial
- The emerging role of the Hippo signaling pathway in interorgan crosstalk.The FEBS journal · 2026Review
- Probiotic and paraprobiotic intervention modulates testicular DNA methylation in streptozotocin-induced diabetic rats: insights into the role of Lactobacillus rhamnosus GG.Scientific reports · 2026Article
- Geospatial clustering of type 1 diabetes in Sweden: a cohort study based on all residential locations from birth to diagnosis.Diabetologia · 2026Article
- Shotgun Metagenomics Reveals Gut Microbiome Remodeling with Altered Taxonomic Composition and Functional Potential in Diabetic Dogs.Animals : an open access journal from MDPI · 2026Article
- Oral GAD65-Microorganisms · 2026Article
- Gut microbiota and the early prevention window in type 1 diabetes and latent autoimmune diabetes in adults: a state-of-the-art narrative review on diet and metabolites.Frontiers in endocrinology · 2026Review
- Immune dysregulation in type 2 diabetes mellitus: Implications for tuberculosis, COVID-19, and HIV/AIDS.Infectious medicine · 2025Review
- Association of the lipidome with type 1 diabetes and the mediated effect of metabolites: A Mendelian randomization study.Medicine · 2025Article
- Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.Integrative medicine (Encinitas, Calif.) · 2025Article
- Pre-Type 1 Diabetes in Adolescents and Teens: Screening, Nutritional Interventions, Beta-Cell Preservation, and Psychosocial Impacts.Journal of clinical medicine · 2025Review
- Variations in gut microbiota in celiac disease patients: a systematic review.Gastroenterology and hepatology from bed to bench · 2025Review
- Dietary Components in the Pathogenesis and Prevention of Type 1 Diabetes in Children.Hormone research in paediatrics · 2025Review
- Human intestinal microbiome: Role in health and disease.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- The Importance of Microbiota and Fecal Microbiota Transplantation in Pancreatic Disorders.Diagnostics (Basel, Switzerland) · 2024Review
- The impact of gut microbiota on autoimmune thyroiditis and relationship with pregnancy outcomes: a review.Frontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this review is to summarize potential modulations of the intestinal microbiome aimed at preventing or delaying progression to overt type 1 diabetes in the light of recently identified perturbations of the gut microbiota associated with the development of type 1 diabetes. RECENT
findingsAccumulated data suggest that the gut microbiota is involved at two different steps in the evolution of type 1 diabetes. At the first step, the intestinal tract is colonized by a microbial community unable to provide an adequate education of the immune system. As a consequence, the infant acquires susceptibility to immune-mediated diseases, type 1 diabetes included. At the other step, the young child seroconverts to positivity for diabetes-associated autoantibodies. This is preceded or accompanied by a decrease in the diversity of the intestinal microbiota and an increased abundance of Bacteroides species. These changes will affect the disease process promoting progression toward overt type 1 diabetes. By providing specific probiotics, one can affect the colonization of the intestinal tract in the newborn infant or strengthen the immune education in early life. Human milk oligosaccharides function as nutrients for "healthy" bacteria. Dietary interventions applying modified starches can influence the numbers and activities of both autoreactive and regulatory T cells and provide protection against autoimmune diabetes in non-obese diabetic mice. Modulation of the intestinal microbiome holds the promise of effective protection against human type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.